EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system

Yamin Shu, Yiling Ding, Lulu Liu, Qilin Zhang iD

CNS Neuroscience & Therapeutics · 2023-09 · 29 (9) · 2705-2716

DOI: 10.1111/cns.14215 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 10.04.2023. Verfasst von Yamin Shu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Antipsychotic Agents, Bipolar Disorder. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Quetiapine, an atypical second‐generation antipsychotic drug, is approved for treatment of schizophrenia, bipolar disorder, and depression. Due to the limitations of clinical trials, the association between quetiapine and rare cardiac adverse events (AEs) is still unclear. This study is to evaluate quetiapine‐associated cardiac AEs through data mining of FDA Adverse Event Reporting System (FAERS).

Methods

Reporting odds ratio (ROR) was used to quantify the signals of quetiapine‐related cardiac AEs from the first quarter (Q1) of 2018–2022 Q1. Serious and nonserious cases were compared, and signals were prioritized using a rating scale.

Results

A total of 1004 cases of quetiapine‐associated cardiac AEs were identified, with 31 signals being detected, among which 13 AEs were identified as new and unexpected signals. Besides, nine and 22 cardiac AEs were identified as moderate and weak clinical priority. The median TTO for moderate and weak clinical priority signals were 0 and 4 days, respectively. All of the cardiac AEs had early failure type characteristics, suggesting that most of the patients developed cardiac AEs in a few days after quetiapine treatment, and that the risk of cardiac AEs occurrence would be gradually decreased over time.

Conclusion

Our study provided valuable evidence for health‐care professionals to mitigate the risk of quetiapine‐associated cardiac AEs based on an extensive analysis of a real‐world, large‐sample FAERS database, and prioritize cardiac AE signals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antipsychotic AgentsBipolar DisorderUnited StatesHumansQuetiapine FumarateAdverse Drug Reaction Reporting SystemsUnited States Food and Drug Administration

Stichwörter der Autor:innen

FAERScardiac adverse eventsdata miningdisproportionality analysispharmacovigilancequetiapine

Substanzen

Quetiapine FumarateAntipsychotic Agents

Autor:innen und Institutionen

  • Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan.
  • School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China.
  • Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

ORCID-Profile: Qilin Zhang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Shu, Y., Ding, Y., Liu, L., & Zhang, Q. (2023). Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system. CNS Neuroscience & Therapeutics, 29(9), 2705-2716. https://doi.org/10.1111/cns.14215

Vancouver

Shu Y, Ding Y, Liu L, Zhang Q. Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system. CNS Neuroscience & Therapeutics. 2023;29(9):2705-2716. doi:10.1111/cns.14215

BibTeX
@article{Shu2023,
  author = {Shu, Yamin and Ding, Yiling and Liu, Lulu and Zhang, Qilin},
  title = {Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system},
  journal = {CNS Neuroscience & Therapeutics},
  year = {2023},
  volume = {29},
  number = {9},
  pages = {2705--2716},
  doi = {10.1111/cns.14215}
}
Kostenlos starten →